MediWound to Participate in Two Upcoming Investor Conferences
MediWound Ltd. (Nasdaq: MDWD) will participate in the Oppenheimer 34th Annual Life Sciences Conference on February 13-14, 2024, and the TD Cowen 44th Annual Health Care Conference on March 4-6, 2024. The management team will host one-on-one meetings during both conferences, and interested investors can schedule meetings through their Oppenheimer and/or TD Cowen representative. Links to access the fireside chat and company presentation will be posted on MediWound’s website. The company is focused on next-generation enzymatic therapeutics for tissue repair.
02/05/2024 - 08:00 AM
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.
Oppenheimer 34 th Annual Life Sciences Conference Date: Tuesday, February 13, 2024 Time: 8:40am ET Location: Virtual Format: Fireside Chat Host: Francois Brisebois, Managing Director & Senior Analyst Webcast Link: Link TD Cowen 44 th Annual Health Care Conference Date: Monday, March 4, 2024 Time: 11:10am ET Location: Boston, MA Format: Presentation Webcast Link: Link
The MediWound management team will host one-on-one meetings during both conferences. Interested investors should contact their Oppenheimer and/or TD Cowen representative to schedule meetings. Links to access the fireside chat and company presentation will also be posted to MediWound’s website on the Events & Presentations page of the Investors section.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care. The Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid® , is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx® . EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the $360 million dominant product and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study.
For more information visit www.mediwound.com and follow the Company on LinkedIn and X .
When is MediWound participating in the Oppenheimer 34th Annual Life Sciences Conference?
MediWound is participating in the Oppenheimer 34th Annual Life Sciences Conference on February 13-14, 2024.
Where will the TD Cowen 44th Annual Health Care Conference take place?
The TD Cowen 44th Annual Health Care Conference will take place in Boston on March 4-6, 2024.
How can interested investors schedule meetings with MediWound's management team during the conferences?
Interested investors can schedule meetings through their Oppenheimer and/or TD Cowen representative.
Where can the links to access the fireside chat and company presentation be found?
Links to access the fireside chat and company presentation will be posted on MediWound’s website on the Events & Presentations page of the Investors section.
MDWD Rankings
#3123 Ranked by Stock Gains
MDWD Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
42 Hayarkon Street
About MDWD
mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and